Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M., Devos, P., Chahine, B., Porte, H., & Lassalle, P. American journal of respiratory and critical care medicine, 173(10):1155–1160, May, 2006. doi abstract bibtex BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%). The AUC for pleural
@article{scherpereel_soluble_2006,
title = {Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.},
volume = {173},
issn = {1073-449X 1073-449X},
doi = {10.1164/rccm.200511-1789OC},
abstract = {BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80\%, specificity = 82.6\%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3\%, specificity = 73.3\%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7\%, specificity = 76.2\%). The AUC for pleural},
language = {eng},
number = {10},
journal = {American journal of respiratory and critical care medicine},
author = {Scherpereel, Arnaud and Grigoriu, Bogdan and Conti, Massimo and Gey, Thomas and Gregoire, Marc and Copin, Marie-Christine and Devos, Patrick and Chahine, Bachar and Porte, Henri and Lassalle, Philippe},
month = may,
year = {2006},
pmid = {16456138},
keywords = {Humans, Female, Prospective Studies, Aged, Male, Middle Aged, Prognosis, Survival Analysis, Neoplasm Staging, Disease Progression, Sensitivity and Specificity, Analysis of Variance, GPI-Linked Proteins, Diagnosis, Differential, Area Under Curve, Asbestosis/metabolism/mortality/*pathology, Biomarkers, Tumor/analysis, Membrane Glycoproteins/analysis/*metabolism, Mesothelioma/blood/mortality/*pathology, Osteopontin, Pleural Effusion, Malignant/*diagnosis/metabolism/mortality, Pleural Neoplasms/blood/mortality/*pathology, Sialoglycoproteins/*metabolism, Solubility},
pages = {1155--1160}
}
Downloads: 0
{"_id":"sQSx8LuZK4FJDkMPp","bibbaseid":"scherpereel-grigoriu-conti-gey-gregoire-copin-devos-chahine-etal-solublemesothelinrelatedpeptidesinthediagnosisofmalignantpleuralmesothelioma-2006","author_short":["Scherpereel, A.","Grigoriu, B.","Conti, M.","Gey, T.","Gregoire, M.","Copin, M.","Devos, P.","Chahine, B.","Porte, H.","Lassalle, P."],"bibdata":{"bibtype":"article","type":"article","title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.","volume":"173","issn":"1073-449X 1073-449X","doi":"10.1164/rccm.200511-1789OC","abstract":"BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%). The AUC for pleural","language":"eng","number":"10","journal":"American journal of respiratory and critical care medicine","author":[{"propositions":[],"lastnames":["Scherpereel"],"firstnames":["Arnaud"],"suffixes":[]},{"propositions":[],"lastnames":["Grigoriu"],"firstnames":["Bogdan"],"suffixes":[]},{"propositions":[],"lastnames":["Conti"],"firstnames":["Massimo"],"suffixes":[]},{"propositions":[],"lastnames":["Gey"],"firstnames":["Thomas"],"suffixes":[]},{"propositions":[],"lastnames":["Gregoire"],"firstnames":["Marc"],"suffixes":[]},{"propositions":[],"lastnames":["Copin"],"firstnames":["Marie-Christine"],"suffixes":[]},{"propositions":[],"lastnames":["Devos"],"firstnames":["Patrick"],"suffixes":[]},{"propositions":[],"lastnames":["Chahine"],"firstnames":["Bachar"],"suffixes":[]},{"propositions":[],"lastnames":["Porte"],"firstnames":["Henri"],"suffixes":[]},{"propositions":[],"lastnames":["Lassalle"],"firstnames":["Philippe"],"suffixes":[]}],"month":"May","year":"2006","pmid":"16456138","keywords":"Humans, Female, Prospective Studies, Aged, Male, Middle Aged, Prognosis, Survival Analysis, Neoplasm Staging, Disease Progression, Sensitivity and Specificity, Analysis of Variance, GPI-Linked Proteins, Diagnosis, Differential, Area Under Curve, Asbestosis/metabolism/mortality/*pathology, Biomarkers, Tumor/analysis, Membrane Glycoproteins/analysis/*metabolism, Mesothelioma/blood/mortality/*pathology, Osteopontin, Pleural Effusion, Malignant/*diagnosis/metabolism/mortality, Pleural Neoplasms/blood/mortality/*pathology, Sialoglycoproteins/*metabolism, Solubility","pages":"1155–1160","bibtex":"@article{scherpereel_soluble_2006,\n\ttitle = {Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.},\n\tvolume = {173},\n\tissn = {1073-449X 1073-449X},\n\tdoi = {10.1164/rccm.200511-1789OC},\n\tabstract = {BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue. Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma. FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L). The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80\\%, specificity = 82.6\\%). The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3\\%, specificity = 73.3\\%). SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L). The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7\\%, specificity = 76.2\\%). The AUC for pleural},\n\tlanguage = {eng},\n\tnumber = {10},\n\tjournal = {American journal of respiratory and critical care medicine},\n\tauthor = {Scherpereel, Arnaud and Grigoriu, Bogdan and Conti, Massimo and Gey, Thomas and Gregoire, Marc and Copin, Marie-Christine and Devos, Patrick and Chahine, Bachar and Porte, Henri and Lassalle, Philippe},\n\tmonth = may,\n\tyear = {2006},\n\tpmid = {16456138},\n\tkeywords = {Humans, Female, Prospective Studies, Aged, Male, Middle Aged, Prognosis, Survival Analysis, Neoplasm Staging, Disease Progression, Sensitivity and Specificity, Analysis of Variance, GPI-Linked Proteins, Diagnosis, Differential, Area Under Curve, Asbestosis/metabolism/mortality/*pathology, Biomarkers, Tumor/analysis, Membrane Glycoproteins/analysis/*metabolism, Mesothelioma/blood/mortality/*pathology, Osteopontin, Pleural Effusion, Malignant/*diagnosis/metabolism/mortality, Pleural Neoplasms/blood/mortality/*pathology, Sialoglycoproteins/*metabolism, Solubility},\n\tpages = {1155--1160}\n}\n\n","author_short":["Scherpereel, A.","Grigoriu, B.","Conti, M.","Gey, T.","Gregoire, M.","Copin, M.","Devos, P.","Chahine, B.","Porte, H.","Lassalle, P."],"key":"scherpereel_soluble_2006","id":"scherpereel_soluble_2006","bibbaseid":"scherpereel-grigoriu-conti-gey-gregoire-copin-devos-chahine-etal-solublemesothelinrelatedpeptidesinthediagnosisofmalignantpleuralmesothelioma-2006","role":"author","urls":{},"keyword":["Humans","Female","Prospective Studies","Aged","Male","Middle Aged","Prognosis","Survival Analysis","Neoplasm Staging","Disease Progression","Sensitivity and Specificity","Analysis of Variance","GPI-Linked Proteins","Diagnosis","Differential","Area Under Curve","Asbestosis/metabolism/mortality/*pathology","Biomarkers","Tumor/analysis","Membrane Glycoproteins/analysis/*metabolism","Mesothelioma/blood/mortality/*pathology","Osteopontin","Pleural Effusion","Malignant/*diagnosis/metabolism/mortality","Pleural Neoplasms/blood/mortality/*pathology","Sialoglycoproteins/*metabolism","Solubility"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://pro.univ-lille.fr/fileadmin/user_upload/pages_pros/patrick_devos/zotero.bib","dataSources":["RjzxJmiLeBgJeLTkb"],"keywords":["humans","female","prospective studies","aged","male","middle aged","prognosis","survival analysis","neoplasm staging","disease progression","sensitivity and specificity","analysis of variance","gpi-linked proteins","diagnosis","differential","area under curve","asbestosis/metabolism/mortality/*pathology","biomarkers","tumor/analysis","membrane glycoproteins/analysis/*metabolism","mesothelioma/blood/mortality/*pathology","osteopontin","pleural effusion","malignant/*diagnosis/metabolism/mortality","pleural neoplasms/blood/mortality/*pathology","sialoglycoproteins/*metabolism","solubility"],"search_terms":["soluble","mesothelin","related","peptides","diagnosis","malignant","pleural","mesothelioma","scherpereel","grigoriu","conti","gey","gregoire","copin","devos","chahine","porte","lassalle"],"title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.","year":2006}